Market Overview

Nektar Therapeutics Says Got Positive Data from Phase 1a Study of NKTR-192

Nektar Therapeutics (Nasdaq: NKTR) announced today that positive data from the first single-ascending dose Phase 1a clinical study of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate, demonstrate that the drug candidate achieved its target pharmacokinetic profile. These data support its continued development as a new analgesic for the treatment of acute pain. The company also announced that dosing has commenced in a second single-ascending dose Phase 1a clinical study of NKTR-192, which will explore the pharmacodynamic profile of this new drug candidate in healthy subjects.

Posted-In: News FDA

 

Related Articles (NKTR)

Around the Web, We're Loving...

Get Benzinga's Newsletters